{"disease":{"id":"candidiasis-invasive","name":"candidiasis invasive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01386437","title":"Natural History of Individuals With Immune System Problems That Lead to Fungal Infections","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04368559","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Mundipharma Research Limited","has_results":false},{"nct_id":"NCT00413218","title":"Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05421858","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":false},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03997929","title":"Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT00608335","title":"Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT05178862","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":68,"lead_sponsor_name":"Scynexis, Inc.","has_results":false},{"nct_id":"NCT01945281","title":"Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05264571","title":"Early Identification of Candida in Intra-abdominal Candidiasis","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05707832","title":"A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03363841","title":"Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT04122560","title":"Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT01165320","title":"A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}